Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Intangibles data on file, last reported at $592.8 million in Q4 2025.

• Intangibles for Q4 2025 came in at $592.8 million, up 117.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $592.8 million (up 117.84% YoY), and the FY2025 annual result was $592.8 million, up 129.9% from the prior year.
• Intangibles improved to $592.8 million in Q4 2025 per TLX's latest filing, from $272.1 million in the prior quarter.
• Over five years, Intangibles peaked at $592.8 million in Q4 2025 and troughed at $71.4 million in Q4 2023.
• A 3-year average of $312.1 million and a median of $272.1 million in 2024 frame the typical range for Intangibles.
• The sharpest annual moves came in 2024 and 2025: Intangibles surged 281.2% in 2024, then surged 117.84% in 2025.
• A 3-year view of Intangibles shows it stood at $71.4 million in 2023, then surged by 281.2% to $272.1 million in 2024, then surged by 117.84% to $592.8 million in 2025.
• Business Quant data shows TLX's Intangibles at $592.8 million in Q4 2025, $272.1 million in Q4 2024, and $71.4 million in Q4 2023.